Portfolio

LifeCell Corporation

Develops and markets biologic products for the repair or replacement of damaged or inadequate tissues.


Rapidly growing tissue regeneration company

LifeCell was headquartered in New Jersey and traded on the NASDAQ under symbol LIFC. The Company develops tissue-based products for use in reconstructive, orthopedic and urogynecologic surgical procedures to repair soft tissue defects. LifeCell’s technology produces a regenerative tissue matrix that creates a biological framework for organizing the same tissue regeneration process that the body undergoes to repair worn or damaged tissue. Leading products include AlloDerm and Strattice. Kinetic Concepts, Inc. (KCI) acquired LifeCell for $1.7 Billion in cash in 2008.

Transaction Summary

  • In 2003, Essex Woodlands acquired a stake in the publicly traded shares of LifeCell.
  • Following the initial growth equity investment, Essex Woodlands worked with LifeCell’s management team to expand market penetration of the core product (AlloDerm) and successfully launch new pipeline products.
  • At the time of EW’s exit, LifeCell was generating over $190M in Sales.
  • Branchburg, NJ
  • NASDAQ: LIFC

  • Contact:
    Marty Sutter
  • Acquisition
  • Acquired by: Kinetic Concepts, Inc.
  • Exit date: April 07, 2008

Related News

““Essex Woodlands was a valuable partner as investors in and advisers to our firm. Their leadership and active participation on our Board, astute and well-informed advice about the capital markets, and entrepreneurial experience and expertise were enabling factors which helped our firm grow into a billion dollar plus company.””

Paul Thomas

Chief Executive Officer

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.